Biotech Power Play: AI and a New Drug Target the $24B Arthritis Market

TEL AVIV, Israel – August 31, 2026 – An upcoming presentation at the prestigious H.C. Wainwright Global Investment Conference is set to offer investors the first detailed look at a newly forged biotech entity poised to disrupt the multi-billion-dollar rheumatoid arthritis market. The event follows the July announcement of a definitive merger agreement between Chemomab Therapeutics (Nasdaq: CMMB), a clinical-stage Israeli firm, and Scipher Medicine, a U.S.-based leader in AI-driven precision immunology.

This is more than a standard corporate merger; it’s a calculated fusion of a promising, first-in-class therapeutic with a powerful artificial intelligence platform designed to predict clinical success. As Chemomab’s CEO, Dr. Adi Mor, prepares to take the virtual stage, the real story for investors is the strategic pivot this combination represents: a plan to advance Chemomab’s lead drug, nebokitug, into a precision-guided Phase 2 trial for rheumatoid arthritis (RA), a complex disease where a staggering number of patients fail to respond to current treatments.

A Lifeline and a Launchpad

The all-stock transaction is structured to create a new, U.S.-domiciled company that will operate as Scipher Medicine Corporation and trade under the ticker "SCIP" on Nasdaq. While the deal signals a bold new chapter, it also serves as a crucial lifeline for Chemomab. The company’s recent financial filings revealed cash reserves of just $6.7 million as of June 30, 2026, and acknowledged "substantial doubt about its ability to continue as a going concern" without fresh capital.

The merger directly addresses this vulnerability. A key condition of the deal is a concurrent Private Investment in Public Equity (PIPE) of at least $30 million, committed by a syndicate of Scipher's high-profile existing investors, including Northpond Ventures, Khosla Ventures, and Blue Owl Healthcare Opportunities. This infusion is projected to provide the combined entity with a cash runway through the second half of 2028, long enough to see the RA trial through to its anticipated data readout.

"This isn't just about survival; it's about creating a fundamentally stronger, more focused company," noted one biotech analyst familiar with the deal. "Chemomab had a valuable asset but was running out of road. Scipher has the AI, the commercial experience, and the financial backing to give that asset its best shot at success in a massive market."

Upon closing, expected before year-end, current Scipher securityholders will own approximately 68% of the new company, with Chemomab holders owning the remaining 32%. Dr. Reginald Seeto, Scipher’s current CEO, will helm the combined organization, while Chemomab's co-founder and CEO, Dr. Adi Mor, will transition to a seat on the board. To ensure Chemomab shareholders retain upside from the company's legacy work, they will also receive Contingent Value Rights (CVRs) tied to potential future milestones for nebokitug in its original, non-RA programs.

De-Risking Development with Data

At the heart of this merger is the synergy between Chemomab's lead asset, nebokitug, and Scipher's proprietary SPECTRA™ platform. Nebokitug is a first-in-class monoclonal antibody that neutralizes CCL24, a protein implicated in driving both inflammation and fibrosis. The drug has already demonstrated a favorable safety profile and disease-modifying potential across five clinical trials, including a Phase 2 study in primary sclerosing cholangitis (PSC), a rare and severe liver disease.

While promising, the path to approval for any new drug is fraught with risk. This is where Scipher’s technology becomes a critical differentiator. The company's AI platform, which analyzes a vast repository of genomic and patient data, was used to scan for the most promising clinical-stage drug candidates for rheumatoid arthritis. According to the companies, SPECTRA™ identified CCL24—the target of nebokitug—as the highest-ranked target for potential efficacy in RA.

The AI's role extends beyond target identification. Scipher believes its platform has also identified a potential therapeutic response signature, a biomarker profile that can predict which RA patients are most likely to benefit from nebokitug. This ability to pre-select a responsive patient population for the upcoming Phase 2 trial is a powerful de-risking tool. "Precision patient selection is the holy grail of drug development," explained a rheumatology expert not involved with the companies. "If you can eliminate likely non-responders from your trial, you dramatically increase your probability of demonstrating a clear clinical benefit."

The combined company plans to initiate this precision-guided Phase 2 trial in the first half of 2027, with topline results expected in the first half of 2028.

Targeting a Crowded Market with Precision

The $24 billion rheumatoid arthritis market is notoriously competitive, dominated by blockbuster biologics and a growing class of oral JAK inhibitors. For a new entrant to succeed, it must offer a significant advantage over the standard of care. The combined company is betting that its advantage lies in addressing the market's most glaring unmet need: treatment failure. An estimated two-thirds of RA patients do not achieve low disease activity or remission with current therapies, leaving them to cycle through different drugs while their disease progresses.

This is a problem Scipher is already tackling. The company developed and markets PrismRA®, a revolutionary blood test that predicts which RA patients will fail to respond to TNF inhibitors, the most commonly prescribed class of biologics. As the only such predictive test approved for coverage by Medicare, PrismRA® has already established Scipher’s credibility in bringing a precision medicine tool from concept to commercial reality.

This track record provides a strong foundation for the nebokitug strategy. By combining a novel therapeutic mechanism—potentially the first new one approved for RA in the U.S. since 2012—with a data-driven patient selection tool, the new Scipher aims to deliver not just another drug, but a complete precision medicine solution.

An Investor Crossroads

The upcoming H.C. Wainwright conference marks a pivotal moment. The joint 1x1 investor meetings co-hosted by Dr. Mor and Dr. Seeto in New York will be the first major test of their unified narrative. Investors will be scrutinizing their plans, seeking confidence that the integration of Chemomab's science and Scipher's AI is more than just a compelling story on paper.

Key questions will revolve around the final details of the merger, the execution timeline for the RA trial, and the strategy for leveraging Scipher's existing commercial infrastructure. The public filing of the Form S-4 registration statement with the SEC, which has already been confidentially submitted, will provide further crucial details for shareholder evaluation.

While the forward-looking statements carry the usual disclaimers of risk, the logic behind this merger is clear. It combines a promising but underfunded asset with a well-capitalized, data-driven engine built to navigate the complexities of modern drug development. For investors, the presentation will be a critical gauge of whether this biotech power play has what it takes to redefine treatment in one of medicine’s most challenging fields.